Support and Financial Assistance for UPTRAVI® (selexipag)

An Actelion Pathways® Case Manager works with your office and the specialty pharmacy to support your patients. When patients are prescribed an Actelion PAH medication and have consented to receive support from Actelion Pathways, they will be contacted by an Actelion Pathways Case Manager or the specialty pharmacy, who can help by:

  • Answering questions about filling prescriptions with a specialty pharmacy
  • Coordinating with you and the specialty pharmacy to help your patients access medicine
  • Informing patients of any financial assistance programs for which they may be eligible

Therapy Access Managers (TAMs)

TAMs serve as the primary field-based lead to support patient access, including starting and staying on Actelion therapies.

See a map of territories to contact the TAM in your area.

Connecting with financial assistance

There are several programs that can provide financial assistance to your patients taking UPTRAVI.

Commercially insured
Patients who receive insurance through your employer or purchase it privately
Actelion Oral PAH Therapy Co-Pay Program* A savings program that lets your eligible patients pay $5 per prescription fill per product. Contact an Actelion Pathways Case Manager for more information. Call 1-866-ACTELION (1-866-228-3546) Mon-Fri, 8 am-8 pm ET.*
Government insured
Patients who receive their medication through Medicare or other government-funded plans
Independent foundations There may be support available from independent third-party patient support foundations. An Actelion Pathways Case Manager can provide general information about resources.
Uninsured or underinsured
Patients who are uninsured or the cost of their medicine is covered by insurance, but are unable to afford the out-of-pocket costs
Patient Assistance Program (PAP) A yearly program that helps patients receive medicine at no cost.
Bridge Program (temporary patient assistance program) Offers 90 days of free drug coverage for patients when coverage is not immediately available (e.g., waiting for coverage to start, waiting for approval of prior authorization appeal, etc).

*Applies to patients who have provided consent to services offered by Actelion Pathways. The Actelion Oral PAH Therapy Co-Pay Program is only available for residents of the US and Puerto Rico who are 18 or older and have commercial health insurance with co-pay/co-insurance exceeding $5 per prescription fill per product. Patients ineligible for the Actelion Oral PAH Therapy Co-Pay Program include those enrolled in Medicare, Medicaid, VA/DoD (Tricare), the Indian Health Service, or any other federal- or state-funded healthcare program, or where prohibited by law. The Actelion Oral PAH Therapy Co-Pay Program is not prescription drug coverage or insurance. Actelion reserves the right to terminate or modify this program at any time or without notice. Other terms and conditions apply.

Support resources

There are also independent organizations that may be able to offer support to your patients:

  • Pulmonary Hypertension Association is dedicated to increasing awareness and advocacy by providing information about PAH to both physicians and patients. Visit their website to learn more
  • The Scleroderma Foundation is a site for scleroderma patients, caregivers, and family members—dedicated to support, education, and research. Visit their website to learn more

Contact an Actelion Pathways Case Manager today. He or she can assist your patients with the support and services provided by Actelion. Call 1-866-ACTELION (1-866-228-3546) Mon-Fri, 8 am-8 pm ET.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI is contraindicated.

WARNINGS AND PRECAUTIONS

Pulmonary Veno-Occlusive Disease (PVOD)

Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI.

ADVERSE REACTIONS

Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%).

See More

INDICATION

UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI is contraindicated.

WARNINGS AND PRECAUTIONS

Pulmonary Veno-Occlusive Disease (PVOD)

Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI.

ADVERSE REACTIONS

Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%).

These adverse reactions are more frequent during the dose titration phase.

Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo.

See More

INDICATION

UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).

DRUG INTERACTIONS

CYP2C8 Inhibitors

Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI with strong inhibitors of CYP2C8 is contraindicated.

Although not studied, use of UPTRAVI with moderate CYP2C8 inhibitors (eg, teriflunomide and deferasirox) can be expected to increase exposure to the active metabolite of selexipag. Consider a less frequent UPTRAVI dosing regimen, eg, once-daily, when initiating in patients on a moderate CYP2C8 inhibitor. Reduce UPTRAVI when initiating a moderate CYP2C8 inhibitor.

CYP2C8 Inducers

Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI when rifampin is stopped.

DOSAGE AND ADMINISTRATION

Recommended Dosage

Recommended starting dose is 200 mcg twice daily. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.

Patients With Hepatic Impairment

For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose is 200 mcg once daily. Increase by 200 mcg once daily at weekly intervals, as tolerated. Avoid use of UPTRAVI in patients with severe hepatic impairment (Child-Pugh class C).

Dosage Strengths

UPTRAVI tablet strengths:
200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg.

Please see full Prescribing Information.